- Bullseye Trades
- Posts
- Post-drop setup forming š¤
Post-drop setup forming š¤
Analysts didnāt flinch... hereās why
*This email contains promotional content
Hey Folks, Jeff Bishop here,
The market inched up today, with traders weighing the prospect of a ceasefire deal with Iran.
We havenāt been in the kind of environment where youād expect small stocks to hold up well.
And yet, one Iāve been tracking has done exactly that.
After investors āsold the newsā earlier this month following a Phase 2 data release, this stock has been steadily consolidating since March 9.
Thatās the kind of behavior I pay very close attention to. In small-cap biotech especially, these āsell the newsā reactions can overshoot realityā¦
And when they do, the reset phase often comes before the next move higher.
What makes this one particularly interesting is that the Phase 2 data itself was positive ā showing a 73% clinical clearance rate in the highest-dose cohort.
But the market didnāt treat it that way.
Instead, the stock got hit hard in the days that followed, dropping roughly 65% from early March highs.
At the same time, analysts following the stock didnāt back off.
In fact, one of the lead firms reaffirmed its āBUYā rating and $27 price target after the data drop.
So the stock drops, but the people paid to analyze the data in detailā¦ stay bullish.
That kind of disconnect is where great ātactical tradeā opportunities can show up.
And right now, the chart is starting to reflect that shift. Selling pressure appears to have dried up and volume has stayed elevated.
At 11:30 AM this morning, thereās a scheduled webcast featuring the principal investigator behind the Phase 2 study ā someone who can actually walk the market through what the data really means clinically.
Iāve broken down exactly what Iām seeing, why this setup stands out right now, and what could come nextā¦
š View Todayās Tactical Trade Idea š
This is one youāll want on your radar before the bell.
Especially with a catalyst hitting in a few hours.
To Your Success,
(ALL are welcome)
DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (āSVā). Full disclaimer: https://bullseyealerts.com/disclaimer/.
NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.
*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received thirty five thousand dollars (cash) from Medicus Pharma, Ltd (via Lifewater Media) for a one day marketing program starting on March 26, 2026 for marketing efforts to increase public awareness of the company mentioned on this page HERE. Please scroll to the bottom for full disclosure details including historical records (if applicable). As SV has received compensation from companies, these parties have financial interests in the securities referenced. SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.
RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.